Nicholas Piramal news from FierceBiotech
NewsTraditional remedies offer opportunities, challenges
The Financial Times delves into the push to develop new therapeutics from traditional Chinese and Indian remedies. There have been successes, including the anti-malarial artemether, which was Read more...
India eyes R&D opportunities
India-based drugs have made a name for themselves as makers of copycat drugs. When a developer's lucrative drug goes off-patent, Indian companies are guaranteed to swoop in and make a less-expensive Read more...
Indian developer inks R&D pact with Merck
China may have seized the spotlight in the Pacific Rim recently with a string of new research Read more...
| Press ReleasesPRESS RELEASE: Nicholas Piramal Announces Drug Discovery and Development Agreement with Merck Nicholas Piramal Announces Drug Discovery and Development Agreement with Merck Mumbai, India 19 November 2007: Nicholas Piramal India Limited and Merck & Co., Inc., which operates in India Read more... |
Paid Research Reports
- Pipeline Insight: Nosocomial Vaccines - Minefield or Goldmine?
- Drug Approval Trends at the FDA and EMEA: Process improvements, heightened scrutiny and industry response
- Biotech 2008 – life sciences industry report (online & print)
- Is there a market for alcoholism pharmacotherapies?
- New report provides Rheumatoid Arthritis market insight